Education
About Us
Working with TipRanks
Follow Us
Valerio Therapeutics (FR:ALVIO)
:ALVIO
ALVIO Stock Chart & Stats
€0.06
<€0.01(1.53%)
At close: 4:00 PM EST
€0.06
<€0.01(1.53%)
Day’s Range― - ―
52-Week Range€0.04 - €0.31
Previous CloseN/A
Volume8.86K
Average Volume (3M)2.72M
Market Cap
€71.30M
Enterprise ValueN/A
Total Cash (Recent Filing)€2.64M
Total Debt (Recent Filing)€18.57M
Price to Earnings (P/E)―
Beta-1.49
Next Earnings
Jul 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding499,448,300
10 Day Avg. Volume496,939
30 Day Avg. Volume2,723,976
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-1.29
Price to Sales (P/S)6.44
P/FCF Ratio-0.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ALVIO FAQ
What was Valerio Therapeutics’s price range in the past 12 months?
Valerio Therapeutics lowest stock price was €0.04 and its highest was €0.31 in the past 12 months.
What is Valerio Therapeutics’s market cap?
Valerio Therapeutics’s market cap is €71.30M.
When is Valerio Therapeutics’s upcoming earnings report date?
Valerio Therapeutics’s upcoming earnings report date is Jul 24, 2025 which is 145 days ago.
How were Valerio Therapeutics’s earnings last quarter?
Valerio Therapeutics released its earnings results on Jul 09, 2025. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is Valerio Therapeutics overvalued?
According to Wall Street analysts Valerio Therapeutics’s price is currently Overvalued.
Does Valerio Therapeutics pay dividends?
Valerio Therapeutics does not currently pay dividends.
What is Valerio Therapeutics’s EPS estimate?
Valerio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valerio Therapeutics have?
Valerio Therapeutics has 499,448,300 shares outstanding.
What happened to Valerio Therapeutics’s price movement after its last earnings report?
Valerio Therapeutics reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.865%.
Which hedge fund is a major shareholder of Valerio Therapeutics?
Currently, no hedge funds are holding shares in FR:ALVIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valerio Therapeutics
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
Technical Analysis
Hybrigenics SA Class A
―
TME Pharma N.V.
―
Biophytis SA
―
Theranexus SA
―
NFL Biosciences SA
―